ADRIATIC Trial: Durvalumab Consolidation Extends Survival in Limited-Stage Small Cell Lung Cancer
Consolidation therapy with the PD-1 immune checkpoint inhibitor durvalumab is set to become the new global standard of care for patients with limited-stage small cell lung cancer (SCLC), according to groundbreaking data presented at the European Society for Medical Oncology (ESMO) Congress 2024. These findings from the phase III ADRIATIC trial represent the first major progress in the treatment of limited-stage SCLC in nearly 40 years.
Tumor Treating Fields Therapy Receives FDA Approval in Metastatic NSCLC
Yesterday, Novocure announced the U.S. Food and Drug Administration (FDA) approval of Optune Lua for concurrent use with PD-1/PD-L1 inhibitors or docetaxel for the treatment of adults with metastatic non–small cell lung cancer (NSCLC) who have experienced disease progression on or after a platinum-based regimen. This wearable treatment device delivers tumor treating fields, which exert physical forces on the electrically charged components of dividing cancer cells, resulting in cell death.
Addition of Ramucirumab to Osimertinib in TKI-Naive EGFR-Mutant Metastatic NSCLC
In an interim analysis of the phase II RAMOSE trial, reported in the Journal of Clinical Oncology, Le et al found that the addition of ramucirumab to osimertinib significantly prolonged progression-free survival as initial treatment in patients with tyrosine kinase inhibitor (TKI)-naive EGFR-mutant metastatic non–small cell lung cancer (NSCLC).
Standard vs Extended Lymphadenectomy in Radical Cystectomy for Muscle-Invasive Bladder Cancer
As reported in The New England Journal of Medicine by Lerner et al, the phase III SWOG S1011 trial showed no disease-free survival benefit for extended vs standard lymphadenectomy in patients with muscle-invasive bladder cancer undergoing radical cystectomy.
Head and Neck Cancer Clinical Trials May Be Becoming Less Diverse, Despite National Efforts
Many patients with head and neck cancer may lack equal opportunity to access experimental treatments in clinical trials or receive treatments that were shown to be effective in similar patients, according to a recent study published by Zuckerman and Edwards in Head & Neck.
IDEA Awardees’ Reflections on the 2024 ASCO Annual Meeting
Ramy Sedhom and colleagues on Optimizing Cancer Care for Older Adults
Ilana Hellmann: Reflections on a Father’s Cancer Journey
Connor J. Kinslow and colleagues on Breast Implant–Related Cancers
Lorcan Ruane and colleagues on Cardiotoxicity: How Far Have We Come?
Sponsored Content
SPONSORED BY THE BREAST CANCER INDEX® TEST BIOTHERANOSTICS, INC. A HOLOGIC COMPANY
Extended Endocrine Therapy for Early-Stage Hormone Receptor–Positive Breast Cancer: Tools for Decision-Making
SPONSORED BY LILLY MEDICAL AFFAIRS
CDK 4/6 Inhibitors for the Treatment of HR-Positive, HER2-Negative High-Risk Early Breast CancerMore Top Stories
Osimertinib Plus Savolitinib: Responses Reported in First-Line Treatment of MET-Aberrant, EGFR-Mutant NSCLC
The combination of the EGFR tyrosine kinase inhibitor osimertinib and the MET inhibitor savolitinib has demonstrated clinically meaningful improvements compared with osimertinib alone as a first-line treatment of patients with de novo MET-aberrant, EGFR-mutant advanced non–small cell lung cancer...
Rogaratinib/Atezolizumab in Cisplatin-Ineligible FGFR mRNA-Overexpressing Urothelial Cancer
In the phase Ib FORT-2 trial reported in JAMA Oncology, Sweis et al found that the combination of the pan-FGFR inhibitor rogaratinib and atezolizumab was active in cisplatin-ineligible patients with locally advanced or metastatic urothelial cancer overexpressing FGFR mRNA. Study Details The study ...
KEYNOTE-811: Pembrolizumab Combination in First-Line Setting Improves Overall Survival in Gastric Cancer
In the final per-protocol analysis of the phase III KEYNOTE-811 trial, an overall survival benefit was shown by adding the PD-1 inhibitor pembrolizumab to trastuzumab and chemotherapy in treatment-naive, unresectable, HER2-positive metastatic gastric or gastroesophageal junction adenocarcinoma.1 ...
Three Days Was Enough
Teresa Hagan Thomas, PhD, BA, RN My dad agreed to receive hospice on a technicality. It happened after weeks of trying to get him home oxygen. My brother drove him to the oncologist’s office, and I helped him get into the wheelchair. He did not complain, but just asked me to hold his coffee...
ACS Program May Reduce Postsurgical Mortality, Improve Care Among Older Patients
Implementing the American College of Surgeons (ACS) Geriatric Surgery Verification program may reduce rates of postsurgical mortality and increase the proportion of patients with documentation standards such as advanced care directives, according to two new studies presented by Horattas et al and...
ADRIATIC Trial: Durvalumab Consolidation Extends Survival in Limited-Stage Small Cell Lung Cancer
Consolidation therapy with the PD-1 immune checkpoint inhibitor durvalumab is set to become the new global standard of care for patients with limited-stage small cell lung cancer (SCLC), according to groundbreaking data presented at the European Society for Medical Oncology (ESMO) Congress 2024.1...
Cancer Diagnoses May Be Linked to Lasting Financial Challenges
Researchers have found that financial fallout can follow patients with cancer and their families as financial bankruptcy, lower credit scores, and other types of financial challenges in the years following a cancer diagnosis, according to two new studies presented by Gomez-Mayorga et al and...
